Clinical Trial Update: Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safety and efficacy of CaPre (NKPL66) in mild-to-high hypertriglyceridemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• CaPre (NKPL66) (NKPL66)

Snippet

Sponsor: Grace Therapeutics Inc. | Conditions: Hypertriglyceridemia | Phase 2 | Status: COMPLETED